NHS National Pharmaceuticals Transition 2019_1 - Contracts Finder Award Notice
What the buyer wrote
NHS National Pharmaceuticals Transition 2019_1 Offer reference number: CM/PHG/17/5547 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 34 months Potential periods of call-offs under the framework agreement: LSNE: 01/10/2019 to 30/04/2020 (7 months) CESW: 01/10/2019 to 30/09/2020 (12 months) NWLN: 01/10/2019 to 28/02/2021 (17 months) Awarded product list bortezomib, arsenic, darunavir, atazanavir, ritonavir, miglustat, gefitinib, carglumic acid, clofaribine, ganciclovir, aprepitant, dexmedetomidine, solifenacin, atomoxetine, atovaquone, metaraminol and olopatadine
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Details
- What the buyer calls it
- NHS National Pharmaceuticals Transition 2019_1 - Contracts Finder Award Notice
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- goods
- Suitable for small firms
- The buyer says yes. What that is worth
- Work starts
- 30 Sep 2019
- Work ends
- 28 Feb 2021
- Kind of work
- Pharmacy and medicines
Who the buyer named
The buyer published a contact address on this notice.